Combination therapy of lymphatic drug delivery and total body irradiation in a metastatic lymph node and lung mouse model. Issue 1 (18th October 2022)

• Record Type: Journal Article
• Authors: Sora, Shota; Sukhbaatar, Ariunbuyan; Fukushige, Shinichi; Mori, Shiro; Sakamoto, Maya; Kodama, Tetsuya
• Is Part Of: Cancer science. Volume 114:Issue 1(2023)
• Page Start: 227
• Page End: 235
• Publication Date: 2022-10-18
• Subjects: chemotherapy -- cisplatin -- lymph node metastasis -- lymphatic drug delivery system -- radiotherapy; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.15562
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Chemotherapy using a lymphatic drug delivery system (LDDS) targeting lymph nodes (LNs) in the early stage of metastasis has a superior antitumor effect to systemic chemotherapy. An LDDS produces a higher drug retention rate and tissue selectivity in LNs. To expand the therapeutic coverage of LDDS from local treatment of metastatic LNs to prevention of distant metastases, the combination of treatment with therapies that enhance systemic tumor immune effects is an important therapeutic strategy. Recently, total body irradiation (TBI) has been shown to activate immune responses and alter the tumor microenvironment. Here we show that combination therapy with TBI and LDDS improves the antitumor effect of metastatic LNs and lung metastasis. Tumor cells were inoculated into the subiliac LN (SiLN) to induce metastasis into the proper axillary LN (PALN) and lung in a mouse model. TBI was carried out on day 4 after inoculation using a gamma irradiator. Lymphatic drug delivery into the accessory axillary LN was used to treat PALN. In vivo bioluminescence imaging, high‐frequency ultrasound, and histology showed that combination therapy using TBI (total dose 1.0 Gy once) and the LDDS suppressed tumor growth in LNs and lung metastases and was more effective than using LDDS or TBI alone. Quantitative RT‐PCR of spleens after combination therapy revealed increased expression of CD4, CD8, and IL‐12b, indicating an activated immune response. The results show that combination therapy with TBI and LDDS is a method to improve the efficacy of LN metastases and distant metastases therapy and is a promising novel approach to treat cancer patients. Abstract : Lymphatic drug delivery system (LDDS) targeting early stage lymph node (LN) metastasis. Middle ‐dose (1.0 Gy) total body irradiation (M‐TBI) was combined with LDDS. Antitumor effects were evaluated using in vivo bioluminescence imaging, high‐frequency ultrasound, histology, and quantitative RT‐PCR. Combination therapy with M‐TBI and LDDS is a promising novel approach to enhance the treatment of micrometastases in early metastatic LNs and distant organs.